Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Profhilo is an injectable skin remodeling treatment containing one of the highest concentrations of hyaluronic acid (HA) on the market. Developed by IBSA Farmaceutici Italia, it is formulated using NAHYCO technology, which creates stabilized hybrid cooperative complexes of high-molecular-weight HA (H-HA) and low-molecular-weight HA (L-HA) through a thermal process, avoiding the use of chemical cross-linking agents like BDDE. Unlike traditional dermal fillers that provide localized volume, Profhilo acts as a bio-remodeler; it spreads through the skin tissues to hydrate the dermis and stimulate the production of four different types of collagen and elastin. It is primarily indicated for the treatment of skin laxity and improvement of skin quality in areas such as the face, neck, and hands.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Profhilo (hyaluronic acid).